AACR logo

More articles from Genomics, Proteomics, and Target Discovery

Abstract CN03-02: Functional genomics approaches to identify targetable dependencies in cancer cells
Mathew Garnett

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) CN03-02; DOI: 10.1158/1535-7163.TARG-19-CN03-02
Abstract PL02-03: The zinc-finger degrome
Quinlan L. Sievers, Georg Petzold, Richard D. Bunker, Aline Renneville, Brian Liddicoat, Wassim Abdulrahman, Tarjei Mikkelsen, Benjamin L. Ebert, Nicolas H. Thoma

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) PL02-03; DOI: 10.1158/1535-7163.TARG-19-PL02-03
Abstract CN03-01: Functional genomics approaches to the discovery of paralog dependencies in cancer
William Sellers

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) CN03-01; DOI: 10.1158/1535-7163.TARG-19-CN03-01
Abstract B029: Comparison of a comprehensive NGS profiling assay and conventional molecular testing approaches for detection of clinically relevant alterations in NSCLC
Elizabeth Weingartner, Kelly M.R. Gerding, Gustavo Cerquiera, Christopher Gault, James Hernandez, Kenneth Valkenburg, Laurel Keefer, Eileen Sagini, Dorhyun Johng, Caitlin Gilley, Colby Ganey, Leila Ettehadieh, Diandra Denier, Christina Oliveras, Kartikeya Joshi, Eric Kong, Eniko Papp, Amy Greer, James R. White, Donna Nichol, John Simmons

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) B029; DOI: 10.1158/1535-7163.TARG-19-B029
Abstract B032: Proteomic analysis reveals alterations in apoptotic signaling machinery in HPV-associated cancers and identifies BRD4 and BCL2 as potential therapeutic targets in HPV-positive HNSCCs
Claudia Heymach, Robert Cardnell, Lixia Diao, Jing Wang, Kwok-Shing Ng, Lauren Byers

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) B032; DOI: 10.1158/1535-7163.TARG-19-B032
Abstract B031: OneThree Biotech’s artificial intelligence platform for optimizing drug development
Coryandar Gilvary, Neel Madhukar, Olivier Elemento

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) B031; DOI: 10.1158/1535-7163.TARG-19-B031
Abstract B023: A reversible SRC-relayed COX2-inflammatory program drives therapeutic resistance in BRAF(V600E) colorectal tumors
Chloe E Atreya, Ana Ruiz-Saenz, Changjun Wang, Bo Pan, Courtney A Dreyer, Diede Brunen, Anirudh Prahallad, Danislav Spassov, Dana J Steffen, Byron C Hann, Scott R VandenBerg, Silvio Gutkind, Mark M Moasser, Laura J van 't Veer, Jean-Philippe Coppe

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) B023; DOI: 10.1158/1535-7163.TARG-19-B023
Abstract B025: Integrative omics analysis decodes cross-talk between signaling pathways to understand the anti-cancer mechanism of TKIs in NSCLC
Guolin Zhang, Karen Ross, Cuneyt Akcora, Katia Smirnova, Bin Fang, John M. Koomen, Eric B. Haura, Mark Grimes

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) B025; DOI: 10.1158/1535-7163.TARG-19-B025
Abstract B027: Analytical validation of a 500+ gene comprehensive NGS assay to detect genomic alterations across 35 tumor types
Kelly M.R. Gerding, Kenneth C Valkenburg, Christina Oliveras, James R. White, Leila Ettehadieh, Gustavo Cerquiera, Christopher Gault, James Hernandez, Eric Kong, Samuel Angiuoli, John Simmons, Isabell Loftin, Abigail McElhinny

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) B027; DOI: 10.1158/1535-7163.TARG-19-B027
Abstract B021: PARP16 is a novel target of talazoparib which contributes to synergy with adavosertib in SCLC
Vinayak Palve, Clare Knezevic, Yunting Luo, Xueli Li, Slivia Novakova, Eric Welsh, Bin Fang, Fumi Kinose, Eric B Haura, Alvaro N Monteiro, John M Koomen, Harshani R Lawrence, Uwe Rix

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) B021; DOI: 10.1158/1535-7163.TARG-19-B021

Main menu

User menu

Search

More articles from Genomics, Proteomics, and Target Discovery

Pages

Articles

Info for

About MCT